Fashion
Wednesday, September 22, 2010
Novartis Gains FDA Approval for Gilenya(TM), a Novel First-line Multiple Sclerosis Treatment Shown to Significantly Reduce Relapses and Delay Disability Progression
Novartis Gains FDA Approval for Gilenya(TM), a Novel First-line Multiple Sclerosis Treatment Shown to Significantly Reduce Relapses and Delay Disability Progression
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment